FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969509349> ?p ?o ?g. }

• W2969509349 abstract "The interaction between tumor cells and their immunosuppressive microenvironment promotes tumor progression and drug resistance. Thus, simultaneously targeting tumor cells and stromal cells is expected to have synergistic antitumor effects. Herein, we present for the first time a preclinical antitumor investigation of 3D185, a novel dual inhibitor targeting FGFRs, which are oncogenic drivers, and CSF-1R, which is the major survival factor for protumor macrophages. The antitumor characteristics of 3D185 were assessed by a range of assays, including kinase profiling, cell viability, cell migration, immunoblotting, CD8+ T cell suppression, and in vivo antitumor efficacy, followed by flow cytometric and immunohistochemical analyses of tumor-infiltrating immune cells and endothelial cells in nude mice and immune-competent mice. 3D185 significantly inhibited the kinase activity of FGFR1/2/3 and CSF-1R, with equal potency and high selectivity over other kinases. 3D185 suppressed FGFR signaling and tumor cell growth in FGFR-driven models both in vitro and in vivo. In addition, 3D185 could inhibit the survival and M2-like polarization of macrophages, reversing the immunosuppressive effect of macrophages on CD8+ T cells as well as CSF1-differentiated macrophage induced-FGFR3-aberrant cancer cell migration. Furthermore, 3D185 inhibited tumor growth via remodeling the tumor microenvironment in TAM-dominated tumor models. 3D185 is a promising antitumor candidate drug that simultaneously targets tumor cells and their immunosuppressive microenvironment and has therapeutic potential due to synergistic effects. Our study provides a solid foundation for the investigation of 3D185 in cancer patients, particularly in patients with aberrant FGFR and abundant macrophages, who respond poorly to classic pan-FGFRi treatment." @default.
• W2969509349 created "2019-08-29" @default.
• W2969509349 creator A5006044740 @default.
• W2969509349 creator A5029048475 @default.
• W2969509349 creator A5030846556 @default.
• W2969509349 creator A5032000137 @default.
• W2969509349 creator A5033602621 @default.
• W2969509349 creator A5038288338 @default.
• W2969509349 creator A5041108474 @default.
• W2969509349 creator A5046981277 @default.
• W2969509349 creator A5060848619 @default.
• W2969509349 creator A5061074781 @default.
• W2969509349 creator A5063800558 @default.
• W2969509349 creator A5068521057 @default.
• W2969509349 creator A5076042387 @default.
• W2969509349 creator A5079785852 @default.
• W2969509349 creator A5089348951 @default.
• W2969509349 creator A5090815103 @default.
• W2969509349 date "2019-08-22" @default.
• W2969509349 modified "2023-10-12" @default.
• W2969509349 title "Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models" @default.
• W2969509349 cites W1505421350 @default.
• W2969509349 cites W1636670860 @default.
• W2969509349 cites W1960850967 @default.
• W2969509349 cites W1965696083 @default.
• W2969509349 cites W1988476050 @default.
• W2969509349 cites W2001717792 @default.
• W2969509349 cites W2015632272 @default.
• W2969509349 cites W2017322644 @default.
• W2969509349 cites W2019711215 @default.
• W2969509349 cites W2024725966 @default.
• W2969509349 cites W2027345033 @default.
• W2969509349 cites W2045420985 @default.
• W2969509349 cites W2049198267 @default.
• W2969509349 cites W2055062505 @default.
• W2969509349 cites W2062265555 @default.
• W2969509349 cites W2076743146 @default.
• W2969509349 cites W2089756110 @default.
• W2969509349 cites W2096156234 @default.
• W2969509349 cites W2096415778 @default.
• W2969509349 cites W2098320019 @default.
• W2969509349 cites W2106465830 @default.
• W2969509349 cites W2110943754 @default.
• W2969509349 cites W2113407988 @default.
• W2969509349 cites W2118291530 @default.
• W2969509349 cites W2122724278 @default.
• W2969509349 cites W2125212831 @default.
• W2969509349 cites W2131088620 @default.
• W2969509349 cites W2141654486 @default.
• W2969509349 cites W2142702787 @default.
• W2969509349 cites W2161579181 @default.
• W2969509349 cites W2161608625 @default.
• W2969509349 cites W2192881333 @default.
• W2969509349 cites W2208494337 @default.
• W2969509349 cites W2224475214 @default.
• W2969509349 cites W2340909673 @default.
• W2969509349 cites W2410004221 @default.
• W2969509349 cites W2464266330 @default.
• W2969509349 cites W2465158514 @default.
• W2969509349 cites W2473042060 @default.
• W2969509349 cites W2521908562 @default.
• W2969509349 cites W2582686270 @default.
• W2969509349 cites W2595713273 @default.
• W2969509349 cites W2597613988 @default.
• W2969509349 cites W2597742783 @default.
• W2969509349 cites W2600903921 @default.
• W2969509349 cites W2728594144 @default.
• W2969509349 cites W2769869838 @default.
• W2969509349 cites W2784371446 @default.
• W2969509349 cites W2797203065 @default.
• W2969509349 cites W2903862273 @default.
• W2969509349 cites W4242386933 @default.
• W2969509349 doi "https://doi.org/10.1186/s13046-019-1357-y" @default.
• W2969509349 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6704710" @default.
• W2969509349 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31438996" @default.
• W2969509349 hasPublicationYear "2019" @default.
• W2969509349 type Work @default.
• W2969509349 sameAs 2969509349 @default.
• W2969509349 citedByCount "21" @default.
• W2969509349 countsByYear W29695093492020 @default.
• W2969509349 countsByYear W29695093492021 @default.
• W2969509349 countsByYear W29695093492022 @default.
• W2969509349 countsByYear W29695093492023 @default.
• W2969509349 crossrefType "journal-article" @default.
• W2969509349 hasAuthorship W2969509349A5006044740 @default.
• W2969509349 hasAuthorship W2969509349A5029048475 @default.
• W2969509349 hasAuthorship W2969509349A5030846556 @default.
• W2969509349 hasAuthorship W2969509349A5032000137 @default.
• W2969509349 hasAuthorship W2969509349A5033602621 @default.
• W2969509349 hasAuthorship W2969509349A5038288338 @default.
• W2969509349 hasAuthorship W2969509349A5041108474 @default.
• W2969509349 hasAuthorship W2969509349A5046981277 @default.
• W2969509349 hasAuthorship W2969509349A5060848619 @default.
• W2969509349 hasAuthorship W2969509349A5061074781 @default.
• W2969509349 hasAuthorship W2969509349A5063800558 @default.
• W2969509349 hasAuthorship W2969509349A5068521057 @default.
• W2969509349 hasAuthorship W2969509349A5076042387 @default.
• W2969509349 hasAuthorship W2969509349A5079785852 @default.
• W2969509349 hasAuthorship W2969509349A5089348951 @default.
• W2969509349 hasAuthorship W2969509349A5090815103 @default.

• next